VEGFA and small cell lung carcinoma: The quadruplet arm of benmelstobart, anlotinib, and platinum etoposide demonstrated an impressive OS (19.3 months versus 11.9 months, HR 0.61, 95% CI 0.47-0.79, P = 0.0002) and PFS benefit (6.9 months vs. 4.2 months, 95% CI 0.0.26-0.41, P < 0.0001), while the triple arm of anlotinib with platinum-etoposide did not demonstrate an OS benefit, lending support for the role of VEGF with immunotherapy in SCLC, though further molecular studies are still needed.